Renal Patient Assistance Program (RPAP)
What is RPAP?
RPAP is designed for patients in financial need who do not have coverage for Renvela® (sevelamer carbonate) (and/or Hectorol® [doxercalciferol injection]) under any prescription drug benefit, including commercial insurance, Medicare, Medicaid, or other government insurance programs.
Through a partnership with the American Kidney Fund (AKF), Sanofi provides qualifying patients with medication at no cost.
Who is eligible for assistance through RPAP?
- Patients who do not have existing drug coverage for Renvela® (sevelamer carbonate) and/or Hectorol® (doxercalciferol injection) under any prescription drug benefit, including commercial insurance, Medicare, Medicaid, or other government insurance programs
- US citizens or legal residents
- A copy of Green Card or Permanent Resident Card is required for legal residents
- Patients in the 90-day waiting period for Medicare coverage
The only formulations of Hectorol® offered are the 4 mcg/2 mL vial and 2 mcg/mL vial.
What documentation is required?
- A Renassist® Insurance Verification Form and Patient Assistance Application (PDF) must be completed and submitted to Renassist via fax or email.
- Medicare A and B beneficiaries having household income below 150% of the Federal
Poverty Level who are applying for Renvela® (sevelamer carbonate) or Hectorol® (doxercalciferol injection) assistance must include one
of the following:
- Official notice of denial or the predecisional notice for the Low-Income Subsidy (Extra Help) from the Social Security Administration
- If applicant is a legal resident, a copy of his/her Green Card or Permanent Resident Card
What is the enrollment process?
- All applications are submitted to Renassist for review of insurance status, and then forwarded to AKF for financial review.
- The healthcare professional and/or the patient will be contacted by fax or phone if an application is incomplete or requires additional information. Please note: incomplete applications will be returned.
- AKF will send an approval or denial letter to the dialysis unit by mail or email.
- Medication will be filled by Diplomat Specialty Pharmacy in up to a 3-month supply with a maximum of 3 refills through the RPAP grant approval date for patients who continue to meet the program criteria.
Is there a need for reenrollment?
- Qualified applicants are required to reapply 1 year from the date the prescription was written.
- Should the patient or healthcare provider have questions regarding the refill process, please contact Renassist.
- T: 1-800-847-0069
- F: 1-877-363-6732
- E: PAP@genzyme.com
8:30 am to 5:00 pm EST
Indication for Renvela and Renagel
Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients
with chronic kidney disease (CKD) on dialysis.
- Sevelamer is contraindicated in patients with bowel obstruction.
- Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
- Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
- Uncommon cases of difficulty swallowing the Renagel (sevelamer hydrochloride) or Renvela® (sevelamer carbonate) tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela® (sevelamer carbonate) suspension in patients with a history of difficulty swallowing.
- Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
- Serum bicarbonate and chloride levels should be monitored.
- Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
- Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.
Indication For Hectorol
Hectorol (doxercalciferol capsules and injection) is indicated for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease (capsules) and in patients with chronic kidney disease on dialysis (capsules and injection).
- You should not take Hectorol if you have a history of abnormally high calcium blood levels (hypercalcemia) or if you have very high vitamin D levels
- Overdosage of any form of vitamin D is dangerous
- Before taking Hectorol, tell your doctor if you have ever had an irregular heartbeat or seizure, or if you are taking any digitalis drugs
- Do not take other vitamin D related drugs if you are currently taking Hectorol
- It is important for anyone taking Hectorol to talk to their doctor before taking any non-prescription drugs or magnesium-containing antacids, and to adhere to instructions about following a low phosphorus diet and calcium supplementation
- One of the main side effects of treatment with Hectorol is hypercalcemia
- Tell your doctor if you experience symptoms of hypercalcemia, such as nausea, vomiting, constipation, loss of appetite, and increased thirst
- Common side effects seen in Hectorol-treated patients not on dialysis (pre-dialysis) were infection, chest pain, constipation, indigestion, anemia, dehydration, depression, muscle tension, sleeplessness, tingling sensation, increased cough, shortness of breath, and runny nose
- Common side effects seen in Hectorol-treated patients on dialysis were headache, ill feeling, slow heartbeat, nausea/vomiting, swelling, dizziness, shortness of breath, and itching
- Hectorol is available by prescription only
- See Hectorol Capsules Full Prescribing Information or Hectorol Injection Full Prescribing Information or call Genzyme Medical Information at 1-800-847-0069.